ダウンロード数: 231

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
29_0009.pdf445.6 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.author辻村, 俊策ja
dc.contributor.author加藤, 次朗ja
dc.contributor.author上田, 公介ja
dc.contributor.author大田黒, 和生ja
dc.contributor.alternativeTsujimura, Shunsakuen
dc.contributor.alternativeKato, Jiroen
dc.contributor.alternativeUeda, Kosukeen
dc.contributor.alternativeOhtaguro, Kazuoen
dc.date.accessioned2010-06-03T04:28:43Z-
dc.date.available2010-06-03T04:28:43Z-
dc.date.issued1983-01-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/120107-
dc.description.abstractEighty-eight cases of urinary bladder tumor were treated in our Department from 1976 to 1978. The effect of so-called immunopotentiators (OK-432, Levamisole and PSK) was studied in 23 patients. The following results were obtained. Pretreatment intracutaneous response to PHA was significantly lower in the high stage and high grade group than in the low stage and low grade group (P less than 0.025). However, there was no correlation between the effect of immunotherapy and PHA skin reaction. Of the immunoglobulins, only IgM was significantly lower in the high grade group than in the low grade group (P less than 0.025). The one-year survival rate for the patients in the high stage group was higher receiving immunotherapy than those not treated. This suggests that immunotherapy may be useful for prolonging the survival time of patients with advanced bladder carcinoma.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.subjectAdjuvants, Immunologic/administration & dosage/therapeutic useen
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/therapeutic useen
dc.subjectBiological Products/therapeutic useen
dc.subjectCarcinoma, Squamous Cell/drug therapy/immunologyen
dc.subjectCarcinoma, Transitional Cell/drug therapy/immunologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLevamisole/administration & dosage/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPhytohemagglutinins/immunologyen
dc.subjectPicibanil/administration & dosage/therapeutic useen
dc.subjectPrognosisen
dc.subjectProteoglycans/administration & dosage/therapeutic useen
dc.subjectSkin Testsen
dc.subjectUrinary Bladder Neoplasms/drug therapy/immunologyen
dc.subject.ndc494.9-
dc.titleいわゆる細胞性免疫能賦活剤を投与した膀胱腫瘍症例の検討ja
dc.title.alternativeTreatment of tumors of the urinary bladder with so-called immunopotentiatorsen
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume29-
dc.identifier.issue1-
dc.identifier.spage9-
dc.identifier.epage15-
dc.textversionpublisher-
dc.sortkey02-
dc.address名古屋市立大学医学部泌尿器科学教室ja
dc.address.alternativeThe Department of Urology, Nagoya City University Medical Schoolen
dc.identifier.pmid6677093-
dcterms.accessRightsopen access-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.29 No.1

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。